{Reference Type}: Journal Article
{Title}: Anti-S Antibodies Against SARS-CoV-2 Infection Among Four Types of Vaccines in Malaysia.
{Author}: Lodz NA;Mat Tamizi NF;Abd Mutalip MH;Ganapathy SS;Lin CZ;Ismail R;Ahmad NA;
{Journal}: Asia Pac J Public Health
{Volume}: 36
{Issue}: 1
{Year}: 2024 Jan 2
{Factor}: 2.27
{DOI}: 10.1177/10105395231223332
{Abstract}: Monitoring SARS-CoV-2 antibody levels can provide insights into a person's immunity to COVID-19 and inform decisions about vaccination and public health measures. Anti-S may be useful as an indicator of an effective immune response. Thus, we conducted this study that aimed to determine the immune response of anti-S antibodies against SARS-CoV-2 for all the vaccine types over time among adult recipients in Malaysia and to determine the associated factors. This study was a cohort that recruited 2513 respondents aged 18 years and above from June to December 2021. Each participant was followed-up for 1-year period from the initial vaccine dose (baseline). We found that the anti-S antibody generally increased for all vaccine types and peaked at two weeks after the second dose vaccination, with Pfizer recipients having the highest median of 100 (100.00-100.00). During the third-month follow-up, the seropositivity of anti-S antibody and the median level decreased for all vaccines. We found that type of vaccines, comorbid status, infection, and booster status were significantly associated with the anti-S antibody level after one year.